Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

Merck Sharp + Dohme Corp.

Abbott Gmbh & Co Kg

Abbvie Deutschland Gmbh and Co Kg

Chung-Ming Hsieh

Lorenzo Benatuil

Yuliya Kutskova

Jennifer Maria Perez

John Memmott

Tariq Ghayur

Chengbin Wu

Jijie Gu

Dominic J Ambrosi

Anca Clabbers

Suju Zhong

Mary Leddy

Margaret Hugunin

Edward B Reilly

Susan Elizabeth Morgan-Lappe

Yingchun Li

Anwar Murtaza

Ulrich Ebert

Martin Schmidt

Maria Harris

Jonathan A Hickson

Erwin R Boghaert

Andrew C Phillips

Charles W Hutchins

Heinz Hillen

Jieyi Wang

Bernhard K Mueller

Andreas R Striebinger

Stefan Barghorn

Reinhold Mueller

Eve H Barlow

Volker Nimmrich

Achim Moeller

Kenton L Longenecker

Alan C Cheng

Michael Roguska

Ian M Tomlinson

Steven Grant

Maria A Argiriadi

Jeanne E Baker

Mihriban Tuna

Gillian A Kingsbury

Edit Tarcsa

Bradford L McRae

Craig Wallace

Shaughn H Bryant

Carrie Goodreau

Enrico L Digiammarino

Zhihong Liu

Mark Anderson

Philip D Bardwell

John E Harlan

Simone Giaisi

Debra Chao

Gerard B Fox

Ralf Loebbert

Archana Thakur

Sahana Bose

Qian Zhang

Alyssa Brito

Ming-Jiu Chen

Zhen Wu

Feng Luo

Feng Dong

Jonathan P Belk

Carl Mieczkowski

Emma Fung

Sophie Parmentier Batteur

Wendy Waegell

Jacqueline G Bixby

Lucia Eaton

Rui Wang

Alexander Ivanov

Jjijie Gu

Rong-rong Zhu

Jianwei Shen

Eileen Belanger

William B Stine

Carrie Enever

Ming-Tang Chen

Sokreine Suon

Russell A Judge

David A Egan

John E Memmott

Mary R Leddy

Phillip D Bardwell

Bernhard K MÜLLER

Yuliya A Kutskova

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

High affinity antibodies targeting tau phosphorylated at serine 413

The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Prolactin receptor binding proteins and uses thereof

The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Anti-CD40 antibodies

The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-EGFR antibodies and antibody drug conjugates

The present invention relates to amyloid-beta (A&#x3b2;) binding proteins. Antibodies of the invention have high affinity to &#x39b;&#x3b2;(20-42) globulomer or any &#x39b;&#x3b2; form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.

Amyloid-beta binding proteins

System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.

High-throughput system and method for identifying antibodies having specific antigen binding activities

Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-&#x3b1;), e.g., human TNF-&#x3b1;, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Immunobinders directed against TNF

Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

IL-17 binding proteins

Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Bispecific antibodies directed against TNF-&#x3b1; and IL-17

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

High-throughput antibody humanization

Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Growing community of inventors

Newton, MA, United States of America

Chung-Ming Hsieh